Pioglitazone, Glimepiride

TANDEMACT 30 mg/2 mg COMPRIMIDOS

30 mg + 2 mg comprimidoSpainMarketedAuthorised 28 Sept 2009

In other countries

The same active substances on other registers, the same brand first.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Pioglitazone, Glimepiride

TANDEMACT 30 mg/2 mg COMPRIMIDOS

30 mg + 2 mg comprimidoSpainMarketedAuthorised 28 Sept 2009

Product informationAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

DUETACT 30/4 mg tabletSaudi Arabia · Takeda GMBH

DuetactUnited States · 2MG; 30MG, 4MG; 30MG · tablet · Takeda Pharms USA

Pioglitazone Hydrochloride and GlimepirideUnited States · 2MG; 30MG, 4MG; 30MG · tablet · Chartwell RX

Packs

Pack	Code	Status
TANDEMACT 30 mg/2 mg COMPRIMIDOS, 28 comprimidos	663162

Documents

The official texts, at the regulator.

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Agencia Española de Medicamentos y Productos Sanitarios

Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.

Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required · Added 12 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substances: Pioglitazone, Glimepiride
Strength: 30 mg + 2 mg
Dosage form: comprimido
Route: vía oral
Register: Spain (AEMPS)
Status: Marketed
Status in the register: Autorizado, comercializado
Authorised: 28 Sept 2009
Registration: 06366018
Marketing authorisation holder: Cheplapharm Arzneimittel Gmbh
Procedure: EU centralised
Supply: Medicamento Sujeto A Prescripción Médica